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The roles of microRNAs on tuberculosis infection: Meaning or myth? 
 
Abstract 
The central proteins for protection against tuberculosis is attributed to interferon-γ, tumor necrosis factor-α, interleukin 
(IL)-6 and IL-1β, while IL-10 primarily suppresses anti-mycobacterial responses. Several studies found alteration of 
expression profile of genes involved in anti-mycobacterial responses in macrophages and natural killer (NK) cells from 
active and latent tuberculosis and from tuberculosis and healthy controls.  This alteration of cellular composition might be 
regulated by microRNAs (miRNAs). Albeit only 1% of the genomic transcripts in mammalian cells encode miRNA, they 
are predicted to control the activity of more than 60% of all protein-coding genes and they have a huge influence in 
pathogenesis theory, diagnosis and treatment approach to some diseases. Several miRNAs have been found to regulate 
T cell differentiation and function and have critical role in regulating the innate function of macrophages, dendritic cells 
and NK cells. Here, we have reviewed the role of miRNAs implicated in tuberculosis infection, especially related to their 
new roles in the molecular pathology of tuberculosis immunology and as new targets for future tuberculosis diagnostics. 
 
Key words: Mycobacterium tuberculosis, tuberculosis infection, microRNA, tuberculosis immunology.   
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1. Introduction 
Tuberculosis remains a major global health problem, causes morbidity among millions of people each year and ranks as 
the second leading cause of death from an infectious disease worldwide.1 The latest estimates suggest approximately 9 
million new cases and 1.4 million tuberculosis deaths in 2011.1 Both innate and adaptive immune responses are required 
for host control of tuberculosis infection.2,3  In tuberculosis pathogenesis, the host cellular immune response determines 
whether an infection is arrested as latent tuberculosis infection (LTBI) or progresses to the next stages, active 
tuberculosis infection. Efficient cell-mediated immunity frequently keeps tuberculosis infection arrested permanently as 
LTBI, but if an infected person cannot control the initial infection in the lung or if the immune system becomes weakened, 
Mycobacterium tuberculosis (M. tuberculosis) can cause active pulmonary or extra pulmonary tuberculosis.4 
Approximately 90% of infected individuals will remain asymptomatic with LTBI and only 10% of the individuals infected 
with M. tuberculosis will develop active disease, suggesting that host genetics factors play an important role to regulate 
progression of tuberculosis infection.5  
 
MicroRNAs (miRNAs) have been identified as important regulators of gene expression at posttranscriptional level and 
influences many biological systems including mammalian immune systems.6 Hundreds of miRNAs encoded in the 
human genome and thousands of target mRNAs have been shown to be involved in cell development, differentiation, 
proliferation, apoptosis, DNA methylation, DNA repair and provide anti-inflammatory or pro-inflammatory stimuli.7,8 Rapid 
advancement in new miRNAs discoveries has continued the possibility that miRNAs will be associated with the 
regulation of almost every aspect of cell physiology. Subsequent reports have identified that miRNAs are associated with 
non-communicable diseases9-15 and communicable diseases.16,17 In addition, miRNAs have potential uses as biomarkers 
for both non-communicable and communicable diseases.18-23  
 
Previous studies revealed altered gene expression profiles in macrophages and natural killer (NK) cells from active and 
latent tuberculosis, tuberculosis-infected and healthy controls.24-28 This alteration of cellular composition and related 
gene expression in tuberculosis patients is likely regulated by miRNAs. Several miRNAs have been found to regulate T 
cell differentiation and function.29-33 In addition, miRNAs have been found to be important in regulating the innate function 
of macrophages, dendritic cells (DCs) and NK cells.31,34,35  Therefore here we will discuss several miRNAs involved in 
molecular pathology of tuberculosis infection and discuss their potential as tuberculosis biomarkers. 
 
2. Discussion 
2.1 The world of microRNAs: Biogenesis, mechanism of action and biological functions  
The human genome encodes only approximately 20,000 protein coding genes, representing <2% of the total genome 
sequence.36,37 However, with advance technology, it was determined that at least 90% of the genome is actively 
transcribed.38 The human transcriptome was found to be more complex than a collection of protein-coding genes and 
their splice variants; showing extensive antisense, overlapping and non-coding RNA (ncRNA) expression.39,40 NcRNAs 
are grouped into two major classes based on transcript size; small ncRNAs and long ncRNAs.41 The small ncRNAs 
class, which includes miRNAs, ranges in length from 18 to 200 nucleotides (nt).41  miRNAs are a class of approximately 
1000 bioinformatically predicted 22-nt length ncRNAs found in eukaryotes.41  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
3 
 
All miRNAs are matured and processed through a multistep process that involves several enzymes first in the cell 
nucleus and finally in the cytoplasm. The primary miRNA transcripts are transcribed as a huge double-stranded primary 
transcript called pri-miRNAs by RNA polymerase II which can be several hundreds nt long.31 Pri-miRNAs fold into hairpin 
structures which are polyadenylated and capped. The RNase III-type enzymes Drosha convert this precursor into a 
double-stranded miRNA precursor of 60- to 100-nt hairpins known as pre-miRNAs.42 Pre-miRNAs contain a local stem-
loop structure that encodes miRNA sequences which are exported from nucleus to cytoplasm by exportin 5.43 
 
In cytoplasm, pre-miRNAs are further processed by the RNase III Dicer to yield imperfect 22-nt double-stranded miRNA. 
This unstable duplex consists of the guide strand (miRNA) and the passenger strand (miRNA*). The guide strand miRNA 
is selected to become a mature miRNA, whereas the miRNA* is degraded.44 The mature miRNA is incorporated into the 
RNA-induced silencing complex (RISC), which recognizes specific targets and induces posttranscriptional gene silencing 
which regulates protein expression.45 An alternative biogenesis pathway was recently discovered in which miRNA enters 
RISC by skipping further processing by Dicer. The strand enters RISC by direct loading of the pre-miRNA after Drosha 
processing.46 
 
Specific miRNAs function is defined by the genes it targets and its effect on their expression. Harapan et al.10 
summarizes several mechanisms, direct and indirect, in which miRNAs repress gene translation in cells. Direct on 
translational repression occurs via initiation block or post-initiation block.  In initiation block, the miRISC inhibits 
translation initiation by interfering with eIF4F-cap recognition and 40S small ribosomal subunit recruitment or by 
antagonizing 60S subunit joining and preventing 80S ribosomal complex formation. Post-initiation block includes 
premature ribosomal drop-off, where the 40S/60S ribosomes are dissociated from mRNA, stalled or slowed elongation, 
the 40S/60S ribosomes are prohibited from joining during the elongation process or facilitating proteolysis of nascent 
polypeptides. The indirect on translational repression occurs via mRNA deadenylation and degradation. In addition, it 
has been reported that the majority of miRNA binding sites are in the 3’ untranslated region (3’UTR) of target mRNA 
molecules and this binding leads to the inhibition of mRNA translation and subsequent degradation.47  
 
Malfunction of miRNA regulation is contributed to the fundamental role biological processes and associate with a variety 
of human diseases. Importantly, miRNA dysregulation may contribute to the broader understanding of the human 
pathologies. Abnormalities can occur by the following ways: (1) loss or down regulation of miRNA expression due to 
mutation, epigenetic inactivation, transcriptional down regulation or abnormality processing,48 (2) overexpression of 
miRNA due to gene amplification or transcriptional upregulation may result in the suppressed production of its target 
proteins,49 (3) a mutation in 3’UTR of an mRNA may affect a miRNA binding site and the miRNA may no longer be able 
to bind,50 and (4) a mutation in 3’UTR of a gene may generate a new miRNA binding site.51 A huge number of studies 
reported that miRNAs dysregulation associated to a wide spectrum of diseases such as chronic kidney disease,9 liver 
cirrhosis,14 systemic sclerosis,15 cardiac fibrosis,13 diabetes,11 pregnancy-related diseases,10,52 and most notably 
cancer.12 Recent studies have shown the regulation of miRNA in human diseases only understood and explained by 
genetic (deletions, mutations and translocation), epigenetic mechanisms (methylation) or abnormalities in the miRNA 
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processing machinery. The contributions of this understanding have been implicated in several infectious diseases, 
providing the prospective use of miRNA as clinical biomarkers.53  
 
In bacterial infections, miRNAs have different mechanisms depending on the characteristic of the bacteria. For example, 
Helicobacter pylori (H. pylori) infection alters the expression of oncogenes, tumor suppressor genes and miRNA in the 
host. Interestingly, a study showed that treat of the infection with anti-H. pylori regiment restored decreased expression 
of several miRNAs.16 In Salmonella infection, treatment of immune cells with bacterial lipopolysaccharide (LPS) led to 
induction of several miRNAs. These results indicate that miRNAs play a role in activation of inflammatory factors when 
mammalian cells are target by bacterial pathogens.54 
 
2.2 Immunology aspect of tuberculosis 
Toll-like receptors (TLRs) are the primary receptors in macrophage used to recognize M. tuberculosis and their signals 
can activate nuclear factor κ beta (NF-κB) to induce proinflammatory cytokines release.55,56  Interferon-γ (IFN-γ) and 
tumor necrosis factor-α (TNF-α) are the main pro-inflammatory cytokines central for protection against to tuberculosis 
infection.26,57,58 TNF-α plays a crucial in controlling M. tuberculosis growth in macrophages through several mechanisms 
and has a central role in the establishment and maintenance of LTBI.59-62  IFN-γ is critical for innate and adaptive 
immunity to infection, especially intracellular bacterial infections.63 Indeed, the crucial role of IFN-γ is well established in 
the protection against M. tuberculosis infection in both mouse models and human.64,65  Moreover, studies suggested for 
a protective role of interleukin-6 (IL-6) and IL-1β in host resistance to M. tuberculosis infection,66,67 while IL-10 primarily 
suppresses anti-mycobacterial responses.68 Therefore, M. tuberculosis lately inhibits production of proinflammatory 
cytokines as a survival mechanism.69  
 
In addition, the ability of M. tuberculosis to reside and replicate within phagocytes allow M. tuberculosis to survive in the 
cell. This mechanism avoids immune response of the cell.70 M. tuberculosis successfully invades and parasitizes 
macrophages by inhibiting phagolysosome fusion and neutralizing the acidic environment of the phagolysosomal 
compartment.71 With a neutralized acidic environment, T cells do not respond to antigens.72  
 
2.3 The role of microRNA in tuberculosis  
2.3.1 microRNA regulation of immune response to tuberculosis  
Several studies revealed altered gene expression profiles in macrophages and NK cells from active and latent 
tuberculosis and from tuberculosis and healthy controls.24-28 This alteration of cellular composition and related gene 
expression in tuberculosis patients is likely regulated by miRNAs. Several miRNAs have been found to regulate T cell 
differentiation and function.29-33 In addition, miRNAs have been found to be important in regulating the innate function of 
macrophages, DCs and NK cells.31,34,35 Here we reviewed the roles of several miRNAs in the molecular pathology of 
tuberculosis.   
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2.3.1.1 miRNA-29 
In vitro and clinical studies documented that miR-29 is overexpressed after virulent Mycobacterium species infection in 
several human cell types.11,73,74 miR-29 suppresses immune responses to M. tuberculosis by downregulating IFN-γ.75 
Beside targeting 3`UTR IFN-γ mRNA, miR-29a promotes the association of IFN-γ mRNA with Argonaute 2 (Ago2) 
protein to form an RNA-induced silencing complex and subsequently suppressed the IFN-γ expression 
posttranscriptionally (Figure 1). Moreover, several reports have indicated that miR-29 also targets the antiapoptotic 
proteins B-cell lymphoma 2 (Bcl-2) and myeloid cell leukemia-1 (Mcl-1), the kinase p85α and the GTP-binding protein 
Cdc42,76,77 thus suggesting a central role for miR-29 in regulating the apoptotic pathway in immune cells. Therefore, 
overexpressed miR-29 in tuberculosis infection partly explain one mechanism by which M. tuberculosis avoids 
macrophage digestion through inhibition of IFN-γ and increasing apoptosis of cells involved anti-tuberculosis responses. 
 
Interestingly, a contrasting phenomenon occurred in a non-virulent Mycobacterium species infection model. 
Mycobacterium bovis Bacillus Calmette-Guerin (BCG) downregulated miR-29 expression and induced IFN-γ expression 
in NK cells and T cells.75 This result indicates miR-29 inhibition may have facilitated IFN-γ production by these T cells 
and expression of miR-29 is influenced by Mycobacterium species-specific virulence.   
 
2.3.1.2 miRNA-147 
Previous study shows that miR-147 is induced upon TLRs/NF-κB signaling pathway in macrophages and attenuates 
expression of proinflammatory cytokines, such as TNF-α and IL-6.78  These results indicate that miR-147 has potent anti-
inflammatory properties. Studies found that TNF-α and IL-6 from serum or peripheral blood mononuclear cells (PBMCs) 
were higher in active tuberculosis compared healthy control.79-81 A key study found that miR-147 was overexpressed in 
sputum obtained from active tuberculosis compared with controls.74 Interestingly, this study found the levels of TNF-α 
and IL-6 in sputum did not differ significantly between active tuberculosis group and controls, indicating cytokines 
dysregulation is mainly occurring in the bloodstream as opposed to the lungs.  Altogether, these facts indicate that miR-
147, together with miR-29 enhance anti-tuberculosis immunity and act as a negative regulator of immune response 
against tuberculosis.   
 
2.3.1.3 miRNA-21 
Previous study suggests miR-21 inhibited proinflammatory cytokines expression and promoted an anti-inflammatory 
cytokine, IL-10, production.82 Recent study found that after M. bovis BCG infection, both in vitro and in vivo; miR-21 is 
upregulated in un-sensitized DCs and macrophages through TLR/Erk/NF-κB pathway.83 miR-21 is also upregulated 
following challenge of macrophages with M. tuberculosis early secreted antigenic target 6 kDa protein (ESAT-6) 
antigen.84 miR-21 inhibited IL-12 expression by directly targeting 3`UTR IL-12 mRNA, and thus suppressed host Th1 
responses (Figure 1). In addition, this study also found that miR-21 downregulated the gene of protective cytokines in M. 
tuberculosis infection (TNF-α and IL-6) but these cytokines levels did not change significantly after ESAT-6 exposure. 
Interestingly, miR-21 also promoted DC apoptosis by targeting Bcl-2, which corroborates previous findings suggesting 
that M. tuberculosis can induce apoptosis of infected cells.85 However, the exact mechanism by which miR-21 regulated 
Bcl-2 expression remains unclear. Furthermore, inhibitors of miR-21 induced IL-12 production and triggered more potent 
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anti-mycobacterial responses. Therefore, miR-21 may be an effective strategy Mycobacteria use to escape the host 
immune response and establish chronic infection. 
 
2.3.1.4 miRNA-99b 
In murine DCs from MyD88-deficient mice, exposure to M. tuberculosis but not to LPS induced overexpression of miR-
99b.86 Further analysis found miR-99b blocking (by antagomirs and knockdown approach) resulted in significantly 
reduced M. tuberculosis growth and significantly upregulated proinflammatory cytokines such as TNF-α, IL-6, IL-12, and 
IL-1β. Inhibition of M. tuberculosis growth might be due to an increase in the production of those proinflammatory 
cytokines. In addition, this study found that miR-99b directly targeted tumor necrosis factor receptor superfamily, 
member 4 (TNFRSF-4) and TNF-α mRNA, to regulate expression of various cytokines and transcription factors involved 
in T cell differentiation pathways and M. tuberculosis clearance (Figure 1). Moreover, treatment of anti-miR-99b-
transfected DCs with anti-TNF-α antibody resulted in increased bacterial death. These data confirmed that miR-99b has 
important role in M. tuberculosis growth in DCs by inhibiting TNF-α production, which allows the bacteria to evade host 
protective immune responses and to survive within host phagocytes.   
 
2.3.1.5 miRNA-125b 
Rajaram et al.87 found that human macrophages incubated with M. tuberculosis and it`s component, lipomannan, induce 
high miR-125b expression with correspondingly low TNF production. miR-125b directly targets 3′UTR of TNF mRNA 
transcript, contributing to the inhibition of translation and possibly its accelerated degradation and downregulates TNF 
production. This study also found that only virulent Mycobacterium species limit activation of mitogen-activated protein 
kinase (MAPK) p38 and Akt, two components that contribute significantly to TNF production in mycobacterial-infected 
macrophages compared with avirulent Mycobacterium species.62,88 miR-125b also enhances the stability of κB-Ras2, an 
inhibitor of NF-κB signaling in human macrophages, thereby decreasing the inflammatory response.89 Taken together, 
these results revealed that M. tuberculosis blocks TNF biosynthesis by upregulating miR-125b (Figure 1). In contrast, 
avirulent Mycobacterium species infection and it`s lipomannan exposure downregulated miR-125b expression which 
correlated with high TNF production. Further analysis found that downregulation of miR-125b increased TNF mRNA 
stability and promote proinflammatory response.  
 
FIGURE 1 
 
2.3.1.6 miRNA-155 
miR-155 has been identified as a multifunctional miRNA involved in a number of biologic processes, including infection, 
inflammation, and immunity.90 Previous study showed knockdown miR-155 mouse model, more IL-4 and less IFN-γ were 
produced, suggesting that miR-155 play an important role in regulating T cell–dependent responses.91 One study found 
debatable results regarding dysregulation of miR-155 in human macrophages that are infected by different 
Mycobacterium species.87 In virulent Mycobacterium species infection model, study found that M. tuberculosis infection 
and it`s lipomannan exposure to human macrophages downregulated miR-155 corresponding low TNF production. This 
downregulation mediated upon TLR-MAPK/Akt pathway. Further analysis revealed that M. tuberculosis leads to reduced 
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translation, by inhibiting initiation, and stability of TNF mRNA. However, these result contradict previous study that found 
miR-155 targeted the 3′UTR of the inositol phosphatase SH2-containing inositol 5-phosphatase (SHIP1) mRNA, a 
negative regulator of TNF production, leading to its degradation, therefore increased TNF production.92 The other study 
also found the expression of miR-155 was shown to increase TNF production through increasing mRNA stability and 
half-life.93  
. 
Results conflicting with Rajaram et al.87 from another study88 suggests M. tuberculosis infection (ESAT-6 antigen 
exposure) in murine macrophage also upregulated miR-155. Furthermore, miR-155 attenuates SHIP1 and the 
transcriptional repressor BTB and CNC homology 1 (Bach1). SHIP1 regulate negatively the activation of the 
serine/threonine kinase AKT while Bach1 is a transcriptional repressor of haem oxygenase-1 (HO-1). AKT is required for 
the survival of M. tuberculosis in macrophages,94,95 and HO-1 is an activator of the M. tuberculosis dormancy. Moreover, 
upregulation of miR-155 inhibit the expression of two modulators of the innate immune response - IL-6 and 
cyclooxygenase-2 (Cox-2). Altogether, these evidences revealed that virulent Mycobacterium species infection 
decreased proinflammatory cytokines. In line with this findings, previous study found evidence that hypervirulent M. 
tuberculosis strain elicit reduced levels of proinflammatory cytokines, including TNF-α and IL-6.96 These results 
corroborate that miR-155 was upregulated in virulent Mycobacterium species and likely offers a survival advantage to 
Mycobacterium within its host (Figure 2). In summary, virulent Mycobacterium species infection in human macrophages 
downregulate miR-155 expression, but infection in murine macrophages upregulate miR-155 expression. This 
controversy needs more comprehensive work to understand the similarities and differences in the response of human 
and murine macrophages with regard to miRNA regulation.  
 
In contrast with virulent Mycobacterium, infection of macrophage with avirulent Mycobacterium species enhance miR-
155 and low miR-125 expression with high TNF production.87 They found that miR-155 increased TNF mRNA stability by 
directly targeting inositol phosphatase SHIP1 3′ UTR, a negative regulator of the PI3K/Akt pathway – a pathway involved 
in TNF biosynthesis,92,93 thereby enhancing PI3K/Akt-mediated signaling and TNF mRNA stability.87 Further analysis 
found that avirulent Mycobacterium species stimulated robust and prolonged MAPK activated protein kinase 2 (MK2) 
phosphorylation, a key molecule for TNF mRNA stability.97 Activated MK2 translocates to the cytoplasm and maintains 
TNF mRNA stability through tristetraprolin (TTP) phosphorylation.98  
 
Another comprehensive study revealed evidences regarding the protective role of miR-155 in avirulent Mycobacterium 
species.99 This study demonstrated that M. bovis BCG upregulated miR-155 by activating TLR2, phosphatidylinositol 3-
kinase (PI3K), protein kinase Cδ (PKCδ), and MAPK pathways, which resulted in the participation of NF-κB and c-ETS in 
transcriptional activation of miR-155 promoter. Further study demonstrated that miR-155 regulates protein kinase A 
(PKA) signaling by directly targeting 3`UTR of protein kinase inhibitor alpha (PKI-α), an endogenous inhibitor of PKA 
activity. PKA is one of the effector kinases that regulate a wide array of cellular responses.84 Consequently, enhanced 
activation of PKA signaling directs the generation of PKA C-α, mediates activation of MAPKs and phosphorylation of 
mitogen and stress-activated protein kinase-1 (MSK1) and cyclic AMP response element binding protein (CREB). This 
complex mechanism modulated expression of apoptosis effectors, activation of caspase-3 and translocation of 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
8 
cytochrome c, thus leading to apoptosis of infected macrophages (Figure 2). It is mean that avirulent Mycobacterium 
species could stimulate the macrophage to undergo apoptosis. However, virulent mycobacteria are likely able to inhibit 
apoptosis by altering the Bcl-2 pathway.100 Previous studies showed that apoptosis is an innate defense function of 
macrophages against M. tuberculosis infection. However, virulent Mycobacterium species caused macrophage death by 
a process that proceeds to necrosis, which produces a permeable cell membrane that enables bacteria to escape and 
spread.72,101  
 
FIGURE 2 
 
 
2.3.1.7 miRNA-144* 
miR-144* is overexpressed in active tuberculosis patients.102 miR-144* target genes in Janus kinase/signal transducers 
and activators of transcription (Jak-STAT) signaling pathway, MAPK signaling pathway, TLR signaling pathway and 
cytokine-cytokine receptor interactions. Further transfection of T cell with miR-144* precursor found that miR-144* inhibit 
TNF-α and IFN-γ production. Since TNF-α and IFN-γ have important role in protective immunity, it is possible that miR-
144* influence the development and outcome of tuberculosis. miR-144* possibly in regulates  anti-tuberculosis immunity 
through modification of cytokine production and cell proliferation of T cells.   
 
2.3.1.8 miRNA-223 and miRNA-424 
Wang et al.28 found that miR-223 and miR-424 were highly expressed in PBMCs from patient with active tuberculosis. A 
miR-223 lost function mouse study showed an increased proration of granulocytes, which are morphologically 
hypermature and hypersensitive to activating stimuli, and have more fungicidal activity.103  miR-424 promotes monocyte 
differentiation and subsequently downregulates expression of the transcription factor NFI-A78.104 Wang et al.28 found 
basic leucine zipper transcription factor 2 / BTB and CNC homology 1 (BACH2) and B-cell CLL/lymphoma 7A (BCL7A) 
are targeted by multiple miRNAs that overexpressed in active tuberculosis. Wang et al.28 hypothesize the reduced 
expression level of these two  genes regulated by multiple miRNAs such as miR-223 and miR-424 may lead to a 
disorder in the proportions of T cells and B cells in active tuberculosis patients, which may disturb the delicate balance of 
immune control in M. tuberculosis infection. Wang et al.28 also found that miR-424 targets BACH2, BCL2, BCL7A, and 
forkhead box O1 (FOXO1) that are involved in cellular differentiation and development, to regulate the differentiation of B 
cells to plasma cell.105  
 
2.3.2 microRNA as biomarker for tuberculosis 
Early diagnosis is essential for effective tuberculosis control and therapy. Current diagnostic approaches relies on the 
detection of the pathogen in clinical specimens. However, due to the heterogeneous clinical presentations of M. 
tuberculosis infection (active tuberculosis disease/asymptomatic LTBI; pulmonary and/or extrapulmonary tuberculosis), 
the development of affordable diagnostic tests based on host biomarkers is urgent in order to improve the quality of the 
TB diagnostic process in paucibacillary or not microbiologically confirmed cases (e.g. children, HIV-positive individuals, 
extrapulmonary cases).106  
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In particular, the mechanisms of LTBI and its transition to active tuberculosis remain elusive. Many studies give 
evidences that this transition occur if it cell-mediated immunity fails.107,108 Previous study revealed altered gene 
expression profiles in macrophages and NK cells from active tuberculosis and LTBI.25 Considering that miRNAs have a 
central role in controlling gene expression, they could represent valuable markers to distinguish active tuberculosis and 
LTBI. Despite several studies focused on cellular miRNAs in in vitro infection experiments, only recently extracellular 
(usually referred as “circulating”) miRNAs have raised attention as tuberculosis biomarkers. Sputum, serum, plasma, or 
other body fluid specimens are readily available and amenable to noninvasive analyses for miRNAs. Indeed, circulating 
miRNAs have been extensively investigated as novel and noninvasive diagnostic and prognostic biomarkers for several 
different diseases, including cancer and infections.19-23,109,110 These routinely taken specimens and robust methods of 
detection make miRNAs ideal biomarkers for disease diagnosis.  Here we provide an overview on the potential role of 
both cellular and circulating miRNAs as biomarkers in tuberculosis. 
 
2.3.2.1 miRNA profiling in blood samples  
Among the studies evaluating miRNA profiles from blood as clinical specimens in tuberculosis, two main categories can 
be defined: serum-based studies and cells-based studies. 
 
a. Serum-based study 
Serum miRNAs are present in a stable form that is protected from endogenous RNase activity.19 The first serum-based 
study found that 92 miRNAs were differentially dysregulated in active pulmonary tuberculosis patients compared with 
healthy controls, of which 59 were upregulated and 33 were downregulated.73 Further validation analysis found that miR-
3125 was downregulated while miR-93* and miR-29a were upregulated in active tuberculosis patients. In addition, 
receiver operating characteristic (ROC) analysis was performed to examine if these miRNAs could be used as a 
diagnostic biomarker for active pulmonary tuberculosis. Analysis found that area under the ROC curve (AUC) of miR-29a 
was 0.831 (Table 1), which reflected that miR-29a has great potential as biomarker to detect active pulmonary 
tuberculosis infection. 
 
TABLE 1 
 
Another study found that 97 miRNAs were differentially expressed in active pulmonary tuberculosis patient sera 
compared with healthy control individuals (90 upregulated and 7 downregulated).111  Validation study showed that the 
expression levels of miR-361-5p, miR-889, miR-576-3p, miR-210, miR-26a, miR-432, and miR-134 were upregulated in 
tuberculosis infected individuals. ROC analysis among these miRNAs, three miRNAs (miR-361-5p, miR-889 and miR-
576-3p) were shown to distinguish active tuberculosis patients from uninfected individuals with moderate sensitivity and 
specificity. In addition, combination of these three miRNAs showed an enhanced ability to discriminate between active 
tuberculosis and healthy individuals with AUC value of 0.863 (Table 1). However, the differences between miR-144* and 
miR-29a expression reported by this study did not significantly differ from the expression previously reported.73 
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Only a recent study compared the serum levels of miRNAs from active tuberculosis patients and patients infected by 
Bordetella pertussis, varicella-zoster virus and enterovirus.111 This study documented that three miRNAs (miR-361-5p, 
miR-889, and miR-576-3p) were overexpressed in tuberculosis patients compared to other infection groups. The 
combination of these miRNAs is suitable biomarkers to differentiate tuberculosis from other microbial infections. Further 
analysis found that these miRNAs target several genes involved in immune system development. For instance, miR-361-
5p target SP-1 transcription factor (SP1) that was a key signaling pathway for IL-10 expression in the lung.112 
 
b. Cells-based study 
The first study profiling miRNA expression in PBMCs from active pulmonary tuberculosis patients and healthy controls 
found that 28 miRNAs were upregulated and 2 miRNAs downregulated in active tuberculosis patients.102 miR-144* was 
one of the miRNA upregulated in active tuberculosis patients. miR-144 was the highest upregulated miRNA observed in 
comparison between active tuberculosis and uninfected individuals in whole-blood cellular miRNA analysis.113  
 
Wang et al.28 conducted a study to compare miRNA expression from PBMCs of active tuberculosis patients and healthy 
controls and found that four miRNAs (miR-144, miR-365, miR-133a and miR-424) were upregulated and three miRNAs 
(miR-500, miR-661 and miR-892b) were downregulated in active tuberculosis patients. Further experimentation 
confirmed that gene expression levels of miR-365 and miR-424 remain significantly different between tuberculosis 
infected and healthy control individuals. Using the software package BRB Array Tool, they found four miRNAs (miR-
130a*, miR-493*, miR-520d-3p, miR-661) upregulated and miR-296-5p downregulated in LTBI compared with healthy 
controls. This study assessed also miRNA expression in PBMCs from active pulmonary patients and LTBI.28 They found 
that 6 miRNAs (miR-21*, miR-223, miR-302a, miR-424, miR-451, miR-486-5p) were upregulated and miR-130b* was 
downregulated in active tuberculosis. However, further testing and validation are needed to determine whether miRNAs 
are useful markers to discriminate active tuberculosis and LTBI.   
 
Maertzdorf et al.113 compared miRNAs expression in serum between active tuberculosis and sarcoidosis patients. This 
study found 145 miRNAs expressed in both diseases. Further analysis documented that four miRNAs (miR-182, miR-
355, miR-15b*, and miR-340) were differentially expressed between these two diseases.  From this study we can see, 
both tuberculosis and sarcoidosis revealed highly similar miRNA profiles. Interestingly, the level of miRNA expression 
significantly differed between these two diseases and healthy control groups that is consistent with the view that miRNAs 
are primarily responsible for fine tuning of responses rather than on/ off switch genes regulating expression.114   
 
T cells tend to be at rest in tuberculosis patients, but can be activated by stimulation of specific antigens. Previously, a 
study documented that Mycobacterium antigen can activate sensitized lymphocytes, leading to elevated inflammatory 
cytokine production for instance IFN-γ in tuberculosis patients after M. tuberculosis purified protein derivative (PPD) 
exposure.115 A study comparing the expression profile PPD–induced miRNAs in PBMCs from tuberculosis patients and 
healthy controls using polymerase chain reaction (PCR) found that only miR-155 and miR-155* were upregulated in 
PBMCs from tuberculosis patients.116 In addition, this study found that the AUC value was 0.897 for miR-155 and 0.794 
for miR-155* (Table 1). Based on the highest likelihood ratio, the elicited sensitivity and specificity were 47.62% and 
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94.74% for miR-155, and 42.86% and 94.74% for miR-155*. This implies that miR-155 and miR-155* may specifically be 
upregulated in the early immune response during resensitization by tuberculosis-specific antigens. A recent in vitro study 
found that miR-155 and miR-146a were significantly elevated in human macrophage after M. tuberculosis infection 
compared to uninfected cells.117 miR-155 and miR-146a are induced following stimulation of TLR ligands and release of 
TNF-α and both TLR and TNF-α signaling are important in mounting the immune response to tuberculosis. Previous 
study also found miR-146a is upregulated following challenge of macrophages with M. tuberculosis ESAT-6 antigen.84 In 
contrast, regarding miR-146a, a recent clinical study found that the expression of miR-146a appeared to be decreased in 
PBMCs of active tuberculosis (pulmonary and extrapulmonary) patients compared with healthy controls.81 miR-146a has 
been previously described as a negative regulator of the immune response118,118 and its systemic downregulation may be 
associated with the exacerbated inflammatory response observed in tuberculosis patients.120 In addition this study also 
found a statistically significant increase in the levels of miR-424 in PBMCs from pulmonary tuberculosis patients 
compared with healthy indiveduals.81  
 
2.3.2.2 miRNA profiling in sputum specimens 
Several studies have shown that miRNAs are stably present in sputum.121,122 Moreover, different studies revealed unique 
dysregulation of miRNAs in sputum in non-infectious lung diseases and has role in the assessment of lung disease.123,124  
Yi et al.74  conducted a study to compare miRNA expression in sputum between active pulmonary tuberculosis patients 
and healthy individuals. This study found that a total of 95 miRNAs (43 miRNAs were overexpressed and 52 miRNAs 
were underexpressed) were differentially expressed between tuberculosis infected and healthy individuals, which was 
further supported by cluster analyses indicating a clear distinction between tuberculosis group and healthy individuals. 
Further validation analysis found that miR-19b-2* was underexpressed while miR-3179 and miR-147 were 
overexpressed in the tuberculosis group compared with controls.  Fu and colleagues73 together with serum miRNA 
profiles, analyzed sputum specimens. In this study miR-93* and miR-29a were present in higher abundance in 
tuberculosis sputum in comparison to in healthy individuals, but only miR-29a overexpression was validated via PCR.73  
 
2.3.2.3 miRNA profiling in pleural fluids  
A recent study found that was no alteration in measured miRNAs level between pleural fluids mononuclear cells (PFMC) 
of tuberculosis patients and healthy individuals.81 In addition,  expression of miRNAs were significantly downregulated in 
PFMCs in comparison to PBMCs. The summary of several miRNAs candidate as possible biomarker to discriminate 
tuberculosis patients and healthy person is provided in Table 2.  
 
TABLE 2 
 
2.3.3 The role of microRNA to evaluate tuberculosis treatment  
Previous study found that H. pylori altered several cellular miRNAs and anti-H. pylori treatment restored miRNAs 
expression to normal level.16 The first study to understand the miRNAs expression profile throughout the course of anti-
tuberculosis treatment recently was published.81 In the beginning of treatment, miR-424 was upregulated and miR-164a 
was downregulated in mononuclear cells of tuberculosis patients. This study found that miR-424 and miR-164a was 
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within normal values after two months of tuberculosis treatment. In addition, blood cytokines analysis indicated that 
active tuberculosis patients had elevated amounts of circulating IL-1β and IL-6 in the beginning of treatment which 
decreased upon tuberculosis treatment, as recorded in previous studies.79,80  Positive association between miR-424 and 
IL-6 may be explained because this miRNA promotes monocyte-macrophage differentiation.124 Additionally, the negative 
relationship between miR-146a and IL-6 in this interaction is consistent with the known role of miR-146a downregulating 
NF-κB.35  Data on the effect of anti-tuberculosis therapy on circulating miRNAs or miRNAs in sputum samples are not 
available yet. 
 
3. Conclusion 
There is significant scientific evidence implicating the central role of miRNAs to modulate a new molecular mechanism of 
pathogenesis in tuberculosis infection. In addition, blood, sputum and pleural fluid-based studies revealed evidence for 
the potential roles of specific miRNAs to discriminate tuberculosis infected and healthy individuals, active and latent 
tuberculosis infections, tuberculosis and other infections and pulmonary diseases, and as biomarkers to evaluate 
tuberculosis treatment outcomes. Therefore, miRNAs stand to increase our understanding in pathogenesis of 
tuberculosis, and might be used as new diagnostic strategies for tuberculosis treatment and control in the next decade.  
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Figure 1. The roles of miRNAs in pathology tuberculosis infection. Several studies revealed evidence that 
Mycobacterium species infection in several cell types upregulated miR-99b, miR-144*, miR-29 and miR-125b. These 
miRNAs target several genes that are important in tuberculosis immunity. Upregulated of these miRNAs help 
Mycobacterial to survival inside host cells and enhance anti-tuberculosis immunity by inhibiting production of 
proinflammatory cytokines and inducing IL-10 through several mechanisms.  Abbreviation: 3`UTR: 3`-untranslated 
region, Ago2: Argonaute 2, IFN-γ: Interferon-γ, IL-12: Interleukin 12, IL-1β: Interleukin 1β, IL-6: Interleukin 6, Jak-STAT: 
Janus kinase/signal transducers and activators of transcription, MAPK: mitogen-activated protein kinase, NF-κB: nuclear 
factor κ beta, TLR: Toll-like receptor, TNFRSF-4: tumor necrosis factor receptor superfamily, member 4, TNF-α: tumor 
necrosis factor-α.  
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Figure 2. The role of miR-155 on virulent (green) and avirulent (yellow) Mycobacterium species infection in macrophage. 
Avirulent Mycobacterium species infection upregulates of miR-155 by triggering the TLR2/PI3K/PKCδ/MAPK signaling 
pathways then recruit of NF-κB and c-ETS to miR-155 promoter. miR-155 induces apoptosis of infected macrophage by 
targeting PKI-α 3`UTR thus increases PKA signaling and finally activates of apoptotic effectors, caspase-3, cytochrome c 
translocation. miR-155 also increases TNF production by increasing TNF mRNA stability. To meet this role, miR-155 
directly targeting SHIP1 3′ UTR, a negative regulator of the PI3K/Akt pathway, a pathway involves in TNF biosynthesis 
and enhances MK2 phosphorylation which is a key molecule for TNF mRNA stability.  Conflict results come from virulent 
Mycobacterium infections. Infection in murine macrophage induces miR-155 expression then attenuates the SHIP1 and 
Bach1 expressions therefore promote mycobacterium dormancy and survival in macrophages. Moreover, upregulation of 
miR-155 inhibits the expression IL-6 and cyclooxygenase-2. However, virulent Mycobacterium infection in human 
macrophage downregulates miR-155. Briefly, this condition decrease TNF production by decreasing TNF mRNA half 
time and decreases PI3K/Akt pathway. Abbreviation. 3`UTR: 3`-untranslated region, Cox-2: cyclooxygenase-2, CREB: 
cyclic AMP response element binding protein, MAPK: mitogen-activated protein kinase,  MK2: MAPK activated protein 
kinase 2, MSK1: mitogen and stress-activated protein kinase-1, NF-κB: nuclear factor κ beta, PI3K: phosphatidylinositol 
3-kinase, PKCδ: protein kinase Cδ, PKI-α: protein kinase inhibitor alpha,  SHIP1: SH2-containing inositol 5-phosphatase, 
TLR: Toll-like receptor.   
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Table 1. Receiver operating characteristic analysis of several microRNAs as tuberculosis biomarker to 
discriminate tuberculosis patient and healthy person 
MicroRNAs Specimen  AUC Author 
miR-292 Blood (serum) 0.831 Fu et al.73 
miR-361 
miR-889 
miR-576-3p 
Combination (miR-361, miR-889 and miR-576-3p)  
Blood (serum) 
Blood (serum) 
Blood (serum) 
Blood (serum) 
0.848 
0.765 
0.711 
0.863 
Qi et al.111 
Qi et al.111  
Qi et al.111  
Qi et al.111 
miR-155 
miR-155* 
Blood (PBMC) 
Blood (PBMC) 
0.897 
0.794 
Wu et al.116 
Wu et al.116 
AUC, area under curve; PBMC, peripheral blood mononuclear cell 
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Table 2. Dysregulation of miRNAs to discriminate tuberculosis patient and healthy person 
Specimens  Dysregulation pattern in tuberculosis compare to healthy person Author 
Blood (serum) Up: miR-144* Liu et al.102 
Blood (serum) Up: miR-361-5p, miR-889 and miR-576-3p Qi et al.111 
Blood (serum) 
Blood (serum) 
Blood (PBMC) 
Up: miR-93* and miR-29a 
Down: miR-3125 
Up: miR-424 and miR-365 
Fu et al.73  
Fu et al.73 
Wang et al.28 
Sputum 
Sputum 
Down: miR-19b-2* 
Up: miR-3179 and miR-147 
Yi et al.74 
Yi et al.74 
Sputum Up: miR-29a Fu et al.73 
Blood (PBMC) and PFMC  Down: miR-146a Spinelli et al.81  
PBMC, peripheral blood mononuclear cell; PFMC, pleural fluids mononuclear cell 
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